In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches

Chunye Zhang<sup>1</sup>, Jiazheng Liu<sup>2</sup>, Yuxiang Sui<sup>3</sup>, Shuai Liu<sup>4</sup>, and Ming Yang<sup>5,6,\*</sup>

<sup>1</sup>Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri 65212, USA;

<sup>2</sup>State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau 999078, China;

<sup>3</sup>School of Life Science, Shanxi Normal University, Linfen, Shanxi province 041004, China;


<sup>4</sup>The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang province 310006, China;


<sup>5</sup>Department of Surgery, University of Missouri, Columbia, Missouri 65212, USA;

<sup>6</sup>NextGen Precision Health Institution, University of Missouri, Columbia, Missouri 65212, USA;

\*Correspondence: yangmin@health.missouri.edu

**Supplementary Figure 1 and legend:** 





**Supplementary Figure 1.** The Root Mean Square Fluctuation (RMSF) of protein and ligands. (A) RMSF of RdRp protein of SARS-CoV-2 with (B) RMSF of ligand Carvedilol. (C) RMSF of RdRp protein with (D) RMSF of ligand 1-hydroxyl carvedilol. (E) RMSF of RdRp protein with (F) RMSF of ligand 3-hydroxyl carvedilol. (G) RMSF of RdRp protein with (H) RMSF of ligand 4-hydroxyl carvedilol. (I) RMSF of RdRp protein with (J) RMSF of ligand 5-hydroxyl carvedilol. (K) RMSF of RdRp protein with (L) RMSF of ligand 8-hydroxyl carvedilol. (M) RMSF of RdRp protein with (N) RMSF of ligand O-desmethyl carvedilol. Ligand contacts are colored with green vertical bars indicating protein residues that interact with the ligands.